Dr. Daver summarizes the four drug approvals for AML in 2017 and how you should be using these treatments in various patient populations.
Published on June 13, 2018 in Treatment
Dr. Daver reviews targeted therapies under investigation, recently approved, and near approval in the treatment of AML.
Published on June 6, 2018 in Treatment
Dr. Carraway discusses the difference between the median time to response and the median time to best response with enasidenib, and how to properly monitor patients on this drug.
Published on May 23, 2018 in Treatment
Dr. Daver discusses the best options, both in current standard of care as well as under investigation, for treating patients unfit for intensive chemotherapy (generally patients above the age of 65).
Published on May 9, 2018 in Treatment
Dr. Lancet explains what we know - and don't know - about therapy-related AML: its causes, features, treatment options, and prognosis.
Published on February 28, 2018 in Treatment
Dr. Pratz discusses how he manages patients with the historically difficult-to-treat relapsed FLT3 ITD acute myeloid leukemia.
Published on January 30, 2018 in Treatment
Dr. Lancet provides a brief overview on where CPX-351 fits into the current treatment paradigm for AML, particularly for patients with high-risk AML.
Published on January 18, 2018 in Treatment
In this interview, Dr. Richard Stone provides his expert overview on trials involving FLT3 inhibitors that may impact future treatment best practices.
Published on January 15, 2018 in Treatment in Clinical Trials
Dr. Lancet discusses the many new therapeutic advances seeking to have an impact on fit, elderly, and relapsed patients, as well as patients with specific targets. Listen to the exciting developments here.
Published on December 15, 2017 in Treatment
Watch Dr. Nazha discuss the future management of older patients with AML, including combining molecular targeted therapies with chemotherapy and other treatment approaches.
Published on November 29, 2017 in Treatment